Passage Bio, Inc. (PASG)
Largest Insider Buys in Sector
PASG Stock Price History Chart
PASG Stock Performance
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the …
Insider Activity of Passage Bio, Inc.
Over the last 12 months, insiders at Passage Bio, Inc. have bought $0 and sold $216,136 worth of Passage Bio, Inc. stock.
On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $23.52M and sold $246,548 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 575,195 shares for transaction amount of $483,164 was made by ORBIMED ADVISORS LLC (10 percent owner) on 2023‑06‑28.
List of Insider Buy and Sell Transactions, Passage Bio, Inc.
| 2024-09-19 | Sale | 10 percent owner | 39,300 0.0645% | $0.71 | $27,903 | -13.09% | ||
| 2024-09-18 | Sale | 10 percent owner | 25,631 0.0432% | $0.73 | $18,711 | -12.67% | ||
| 2024-09-17 | Sale | 10 percent owner | 111,400 0.181% | $0.73 | $81,322 | -15.62% | ||
| 2024-09-16 | Sale | 10 percent owner | 63,100 0.1035% | $0.74 | $46,694 | -15.81% | ||
| 2024-02-13 | Sale | CHIEF MEDICAL OFFICER | 1,638 0.0029% | $0.97 | $1,589 | +14.65% | ||
| 2024-02-13 | Sale | SVP, INTERIM CFO | 1,470 0.0026% | $0.97 | $1,426 | +14.65% | ||
| 2024-01-02 | Sale | GC & Corporate Secretary | 15,813 0.0291% | $0.91 | $14,390 | +11.96% | ||
| 2024-01-02 | Sale | Chief Medical Officer | 15,813 0.0291% | $0.91 | $14,390 | +11.96% | ||
| 2024-01-02 | Sale | SVP, Interim CFO | 10,672 0.0197% | $0.91 | $9,712 | +11.96% | ||
| 2023-07-28 | Sale | Chief Financial Officer | 11,453 0.021% | $0.88 | $10,079 | +5.64% | ||
| 2023-06-28 | 10 percent owner | 575,195 1.0841% | $0.84 | $483,164 | +14.66% | |||
| 2023-06-27 | 10 percent owner | 617,382 1.144% | $0.84 | $518,601 | +12.39% | |||
| 2023-06-16 | Sale | Chief Technical Officer | 4,052 0.0072% | $0.93 | $3,778 | -3.38% | ||
| 2023-04-18 | Sale | Chief Financial Officer | 2,053 0.0037% | $1.05 | $2,156 | -13.13% | ||
| 2022-12-01 | Sale | director | 5,000 0.0092% | $1.19 | $5,965 | -17.48% | ||
| 2022-11-22 | Sale | Chief Technical Officer | 3,720 0.0076% | $1.33 | $4,948 | -17.38% | ||
| 2022-09-19 | Sale | Chief Commercial Officer | 1,681 0.0029% | $1.51 | $2,539 | -32.92% | ||
| 2022-05-03 | 221,500 0.401% | $1.93 | $427,495 | -27.04% | ||||
| 2022-03-21 | CEO and President | 10,000 0.0188% | $3.15 | $31,500 | -45.31% | |||
| 2022-01-20 | 10 percent owner | 50,800 0.0975% | $5.00 | $254,000 | -58.13% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 7794569 12.6192% | $0.63 | 10 | 4 | <0.0001% |
| Cale Edgar B. | GC & Corporate Secretary | 45995 0.0745% | $0.63 | 1 | 1 | <0.0001% |
| OrbiMed Capital GP VII LLC | 6537923 10.5848% | $0.63 | 1 | 0 | <0.0001% | |
| Heron Patrick J | 5009219 8.1098% | $0.63 | 1 | 0 | <0.0001% | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 5009219 8.1098% | $0.63 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $13.67M | 16.43 | 10.12M | 0% | +$0 | 0.11 | |
| Versant Ventures | $6.7M | 8.05 | 4.96M | 0% | +$0 | 6.49 | |
| Lynx1 Capital Management Lp | $6.54M | 7.86 | 4.85M | +1,178.06% | +$6.03M | 0.35 | |
| New Leaf Venture Partners | $3.37M | 4.05 | 2.5M | 0% | +$0 | 3.21 | |
| The Vanguard Group | $2.8M | 3.36 | 2.07M | +2.61% | +$71,085.59 | <0.0001 |